INHIBIKASE THERAPEUTICS INC (IKT)
US45719W2052 - Common Stock
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | ||
|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 3.1M 342.86% | 120K -96.13% | 260.5K 117.08% | -100.00% | |||
| EBITDA YoY % growth | N/A | -18.12M | -19.912M -9.89% | N/A | N/A | N/A | |
| EBIT YoY % growth | -14.77M -423.76% | -18.13M -22.75% | -20.09M -10.81% | -22.086M -9.93% | -35.229M -59.51% | -46.208M -31.17% | |
| Operating Margin | -476.45% | -15,108.33% | -7,712.01% | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | -4.32 8.61% | -3.57 17.36% | -0.91 74.44% | -0.46 49.82% | -0.56 -22.80% |
All data in USD
| Q4 / 24 | Q1 / 25 | Q2 / 25 | Q3 / 25 | Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.09 86.32% | -0.11 84.78% | -0.12 81.64% | -0.14 78.25% | -0.15 -73.07% | -0.17 -54.55% | -0.18 -50.00% | -0.20 -42.86% | -0.21 -40.00% |
| Revenue Q2Q % growth | |||||||||
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -6.255M -42.05% | -7.272M -52.06% | -8.282M -63.98% | -9.393M -61.18% | -10.403M -66.31% | -11.514M -58.33% | -12.625M -52.44% | -13.736M -46.24% | -14.847M -42.72% |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q3 2024 Q2Q % growth | -0.65 24.42% | -0.37 | -0.28 | -73.94% |
| Q2 2024 Q2Q % growth | -0.66 40.54% | -0.68 | 0.02 | 2.47% |
| Q1 2024 Q2Q % growth | -0.73 23.96% | -0.80 | 0.07 | 8.51% |
| Q4 2023 Q2Q % growth | -0.64 40.74% | -0.86 | 0.22 | 25.45% |
| Q3 2023 Q2Q % growth | -0.86 20.37% | -1.13 | 0.27 | 23.97% |
| Q2 2023 Q2Q % growth | -1.11 -2.78% | -0.93 | -0.18 | -19.46% |
| Q1 2023 Q2Q % growth | -0.96 11.11% | -0.88 | -0.08 | -9.25% |
| Q4 2022 Q2Q % growth | -1.08 10.00% | -1.15 | 0.07 | 6.20% |
| Q3 2022 Q2Q % growth | -1.08 -500.00% | -1.09 | 0.01 | 0.99% |
| Q2 2022 Q2Q % growth | -1.08 -390.91% | -1.15 | 0.07 | 6.20% |
| Q1 2022 Q2Q % growth | -1.08 -315.38% | -1.03 | -0.05 | -4.83% |
| Q4 2021 Q2Q % growth | -1.20 -700.00% | -1.03 | -0.17 | -16.48% |
| Q3 2021 Q2Q % growth | -0.18 | -0.14 | -0.04 | -27.30% |
| Q2 2021 Q2Q % growth | -0.22 | -0.38 | 0.16 | 42.68% |
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q3 2024 Q2Q % growth | -100.00% | % | ||
| Q4 2023 Q2Q % growth | -100.00% | % | ||
| Q3 2023 Q2Q % growth | 79K 690.00% | 79K | % | |
| Q2 2023 Q2Q % growth | 120K -100.00% | % | ||
| Q1 2023 Q2Q % growth | 60K -100.00% | % | ||
| Q3 2022 Q2Q % growth | 10K -96.97% | 202K | -192K | -95.05% |
| Q2 2022 Q2Q % growth | 10K -99.26% | 303K | -293K | -96.70% |
| Q1 2022 Q2Q % growth | 50K -96.45% | 303K | -253K | -83.50% |
| Q4 2021 Q2Q % growth | -100.00% | 303K | -303K | -100.00% |
| Q3 2021 Q2Q % growth | 330K 725.00% | 303K | 27K | 8.91% |
| Q2 2021 Q2Q % growth | 1.36M 518.18% | 303K | 1.057M | 348.84% |
| Q1 2021 Q2Q % growth | 1.41M 422.22% | % | ||
| Q4 2020 Q2Q % growth | 170K -29.17% | % | ||
| Q3 2020 Q2Q % growth | 40K -66.67% | % | ||
| Q2 2020 Q2Q % growth | 220K 29.41% | % | ||
| Q1 2020 Q2Q % growth | 270K -54.24% | % | ||
| Q4 2019 Q2Q % growth | 240K -82.22% | % | ||
| Q1 2019 Q2Q % growth | 590K -14.49% | % |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | -30% | 75.93% | -57.1% | 64.44% |
| Revenue | N/A | N/A | N/A | N/A |